抗治疗的高血压揭示巨细胞动脉炎:一个病例报告
Dr Lakrafi Yassir1, Professor Mina Moudatir2, Professor Khadija Echchilali2
1Internal Medicine Department and Geriatrics Unit of the Ibn Rochd University Hospital Center in Casablanca.
The American journal of medicine
|March 6, 2026
概括
巨细胞动脉炎可以呈现异常. 耐药性高血压和整体恶化可能标志着这种大血管血管炎,即使没有经典症状.
科学领域:
- 类风湿病学 类风湿病学
- 内部医学 内部医学
- 血管医学 血管医学
背景情况:
- 巨细胞动脉炎 (GCA),也称为霍顿病,是一种炎症性大血管血管炎.
- 它主要影响50岁以上的人,女性占主导地位,病因不明.
- 由于异质和非特异性临床表现,诊断具有挑战性.
研究的目的:
- 为了突出巨细胞动脉炎的诊断复杂性.
- 为了强调这种情况的非典型表现.
主要方法:
- 一个68岁的老人患有新发炎性高血压和头痛的病例报告.
- 通过组织学,CT血管学和PET/CT成像进行诊断确认.
- 通过定期检查排除其他疾病.
主要成果:
- 患者出现了无法控制的动脉高血压和整体恶化.
- 观察到一种长时间的炎症综合征.
- 巨细胞动脉炎最终通过多种成像方式和组织学证实.
结论:
- 巨细胞动脉炎可能并不总是表现出典型的症状,如头痛或关节硬化.
- 耐药性动脉高血压和整体恶化是怀疑GCA的关键指标.
- 这一案例强调了在非典型的呈现中考虑GCA的重要性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
609
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609
Hypertension III: Clinical Manifestations and Diagnostic Studies
690
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
690
Aneurysm III: Interprofessional Care
422
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
422
Aortic Regurgitation III: Medical Management
526
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
526
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
519
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K


